At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 880 enrolled
Drug / intervention
placebo +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Equivalence Study of Mometasone Nasal Spray
In Brief
A Phase 3 clinical trial evaluating placebo, Mometasone Nasal Spray, and 1 other intervention for Seasonal Allergic Rhinitis. Completed, enrolled 880 participants across 25 sites.
Detailed Summary
A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Site Study to Compare the Clinical Equivalence of Mometasone Nasal Spray (Watson Laboratories, Inc) with NASONEX® Nasal Spray (Schering Corporation) in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeasonal Allergic Rhinitis
CountriesUnited States
CollaboratorsWatson Laboratories, Inc.
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2013
First PostedMay 2013
Primary CompletionDec 2013
TodayJul 2026
First PostedMay 10, 2013
Enrollment StartFeb 1, 2013
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 13.1 years ago
Interventions
placebodrug
Mometasone Nasal Spraydrug
Mometasone nasal spraydrug